Molecular Diagnostics VL

Perspective on Molecular Characterization - Himisha Beltran

Details
Himisha Beltran, presents the Perspective on Molecular Characterization and what we can expect looking forward over the next 24 months. (presentation in 6:25). Biography: Misha Beltran, MD is a medical oncologist specializing in the treatment of patients with genitourinary malignancies. Her clinical and translational research focuses on development of new treatment strategies for patients. In part...

Patients with Familial Prostate Cancer: Practical Implications and Recommendations - Ros Eeles

Details
Access to all Advanced Prostate Cancer Consensus Conference Video Coverage Read the 2017 APCCC Report on Management of Patients with Advanced Prostate Cancer

Tumor Biopsy in Men With Metastatic Prostate Cancer: What Should the Pathologist Report? - Mark Rubin

Details
Access to all Advanced Prostate Cancer Consensus Conference Video Coverage Read the 2017 APCCC Report on Management of Patients with Advanced Prostate Cancer

Pathological Information Needed From Radical Prostatectomy Specimen for Locally Advanced Disease: Margins, Lymph Nodes, and What Else? - Neal Shore

Details
Access to all Advanced Prostate Cancer Consensus Conference Video Coverage Read the 2017 APCCC Report on Management of Patients with Advanced Prostate Cancer

Acting on Molecular Sub-Types - Johann de Bono

Details
Access to all Advanced Prostate Cancer Consensus Conference Video Coverage Read the 2017 APCCC Report on Management of Patients with Advanced Prostate Cancer

Aggressive Variants of Prostate Cancer: When to Look and How to Treat? - Himisha Beltran

Details
Access to all Advanced Prostate Cancer Consensus Conference Video Coverage Read the 2017 APCCC Report on Management of Patients with Advanced Prostate Cancer

Circulating tumor cells: Ready for Prime time?- Howard Scher

Details
Howard Scher discusses the readiness of liquid biopsy and the process required to make the possibilities of predictive biomarkers a reality. What is needed are assays for predictive biomarkers in circulating tumor cells (CTCs) to inform choice of the treatment at decision points in patient management. He discusses the challenges in demonstrating clinical utility which is the use of the test result...

Colin Pritchard on Germline and Somatic DNA in Men with Castration-Resistant Prostate Cancer

Details
Colin Pritchard, PhD, presented, "Next-generation or targeted sequencing of germline and somatic DNA in men with CRPC" at the 2017 Advanced Prostate Cancer Consensus Conference: (APCCC) in St. Gallen, Switzerland. Charles Ryan, MD, interviewed Dr. Pritchard on reading a mutation panel and what to look at and what to disregard. Also, the classification scheme which is used by most labs and his thou...